浩欧博:2025一季报净利润0.02亿 同比下降50%

Financial Performance - The company's basic earnings per share decreased by 50% to 0.0300 yuan in Q1 2025 compared to Q1 2024, which was 0.0600 yuan [1] - Net profit for Q1 2025 was 0.02 billion yuan, down 50% from 0.04 billion yuan in Q1 2024 [1] - Operating revenue fell by 9.3% to 0.78 billion yuan in Q1 2025 from 0.86 billion yuan in Q1 2024 [1] - The return on equity (ROE) dropped significantly by 57.45% to 0.20% in Q1 2025 from 0.47% in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 46.4623 million shares, accounting for 73.68% of the circulating shares, with a decrease of 556,100 shares compared to the previous period [1] - Beijing Huiguang Runkang Pharmaceutical Development Co., Ltd. remains the largest shareholder with 18.6709 million shares, representing 29.61% of total share capital [2] - New entrants among the top shareholders include Shuangrun Zheng'an Information Consulting (Beijing) Co., Ltd. with 14.3262 million shares, accounting for 22.72% [2] Dividend Policy - The company has announced that it will not distribute dividends or allocate shares this time [3]